Jönsson B - Search Results

1

Advantages of using the net-benefit approach for analysing uncertainty in economic evaluation studies.

Zethraeus N, Johannesson M, Jönsson B, Löthgren M, Tambour M. Zethraeus N, et al. Among authors: jonsson b. Pharmacoeconomics. 2003;21(1):39-48. doi: 10.2165/00019053-200321010-00003. Pharmacoeconomics. 2003. PMID: 12484802 Review.

2

Cost effectiveness of alendronate for the treatment of male osteoporosis in Sweden.

Borgström F, Johnell O, Jönsson B, Zethraeus N, Sen SS. Borgström F, et al. Among authors: jonsson b. Bone. 2004 Jun;34(6):1064-71. doi: 10.1016/j.bone.2003.12.028. Bone. 2004. PMID: 15193554

3

Reassessment of the cost-effectiveness of hormone replacement therapy in Sweden: results based on the Women's Health Initiative randomized controlled trial.

Zethraeus N, Borgström F, Jönsson B, Kanis J. Zethraeus N, et al. Among authors: jonsson b. Int J Technol Assess Health Care. 2005 Fall;21(4):433-41. doi: 10.1017/S0266462305050609. Int J Technol Assess Health Care. 2005. PMID: 16262965 Clinical Trial.

4

Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: a model for Europe and Australia.

Lindgren P, Jönsson B, Redaelli A, Radice D. Lindgren P, et al. Among authors: jonsson b. Pharmacoeconomics. 2002;20(2):101-8. doi: 10.2165/00019053-200220020-00003. Pharmacoeconomics. 2002. PMID: 11888362

5

Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study.

Borgström F, Johnell O, Kanis JA, Oden A, Sykes D, Jönsson B. Borgström F, et al. Among authors: jonsson b. Pharmacoeconomics. 2004;22(17):1153-65. doi: 10.2165/00019053-200422170-00005. Pharmacoeconomics. 2004. PMID: 15612833

6

Changing health environment: the challenge to demonstrate cost-effectiveness of new compounds.

Jönsson B. Jönsson B. Pharmacoeconomics. 2004;22 Suppl 4:5-10. doi: 10.2165/00019053-200422004-00003. Pharmacoeconomics. 2004. PMID: 15876007 Review.

7

Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Borgström F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Lunsjö K, Thorngren KG, Sernbo I, Rehnberg C, Jönsson B. Borgström F, et al. Among authors: jonsson b. Osteoporos Int. 2006;17(5):637-50. doi: 10.1007/s00198-005-0015-8. Epub 2005 Nov 9. Osteoporos Int. 2006. PMID: 16283064

8

Long-term cost and effect on quality of life of osteoporosis-related fractures in Sweden.

Ström O, Borgstrom F, Zethraeus N, Johnell O, Lidgren L, Ponzer S, Svensson O, Abdon P, Ornstein E, Ceder L, Thorngren KG, Sernbo I, Jonsson B. Ström O, et al. Among authors: jonsson b. Acta Orthop. 2008 Apr;79(2):269-80. doi: 10.1080/17453670710015094. Acta Orthop. 2008. PMID: 18484255 Free article.

9

Intervention thresholds for osteoporosis in the UK.

Kanis JA, Borgstrom F, Zethraeus N, Johnell O, Oden A, Jönsson B. Kanis JA, et al. Among authors: jonsson b. Bone. 2005 Jan;36(1):22-32. doi: 10.1016/j.bone.2004.08.018. Epub 2004 Dec 15. Bone. 2005. PMID: 15663999

10

The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.

Lindgren P, Buxton M, Kahan T, Poulter NR, Dahlöf B, Sever PS, Wedel H, Jönsson B; ASCOT investigators. Lindgren P, et al. Among authors: jonsson b. Pharmacoeconomics. 2009;27(3):221-30. doi: 10.2165/00019053-200927030-00005. Pharmacoeconomics. 2009. PMID: 19354342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,559 results

Search Page